Founded in 2020, Shanghai Immunocan Biotech Co., Ltd. is a biotechnology company dedicated to building antibody drug discovery platforms using innovative gene editing technology. Our goal is to empower global antibody drug R&D with proprietary gene-edited animal platform generating human and alpaca antibody, suitable for different drug discovery scenarios.
As the world's leading gene editing and replacement technology, MASIRT® represents a revolutionary breakthrough that enables cross-species in situ replacement of DNA fragments at the megabase scale, in a time-efficient and species-neutral manner. ImmuMab® Mouse is a fully human antibody generation platform created based on MASIRT®technology.